Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 22, 2025.

via HealthDay

TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs, according to a study published online July 15 in JAMA Network Open.

Huan-Tang Lin, M.D., Ph.D., from Chang Gung Memorial Hospital at Linkou in Taiwan, and colleagues examined the association of semaglutide and tirzepatide with the incidence of dementia, Parkinson disease, ischemic stroke, intracerebral hemorrhage, and all-cause mortality compared to other antidiabetic drugs in a retrospective cohort study analyzing electronic health record-based data for adults aged 40 years or older with type 2 diabetes and obesity.

The study included 60,860 adults with type 2 diabetes and obesity: 30,430 in the GLP-1 RA group and 30,430 in the other antidiabetic drug group (biguanides, sulfonylureas, dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, thiazolidinediones, and α-glucosidase inhibitors) after propensity score matching. The researchers found that GLP-1 RA users had a lower risk for dementia, ischemic stroke, and all-cause mortality during a seven-year follow-up (hazard ratios, 0.63, 0.81, and 0.70, respectively), while no significant differences were seen in the risks for Parkinson disease or intracerebral hemorrhage. Greater benefits were seen for those aged 60 years or older, women, and patients with a body mass index of 30 to 40 kg/m2.

"These findings highlight the possible role of GLP-1 RAs in mitigating neurodegenerative and cerebrovascular risks in this high-risk population," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-23 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords